News Author: Thomas R. Collins Publish date: March 1, 2018
The HM18 schedule provides more flexibility than previous conferences, and attendees have more choices.
News Author: Thomas R. Collins Publish date: January 9, 2018
More than 1,000 physicians in the Phoenix metro area are part of a hospital network with incentive-laden contracts for meeting care and wellness go...
News Author: Thomas R. Collins Publish date: October 27, 2017
Sequencing therapy in chronic lymphocytic leukemia depends on patient characteristics, prior therapy, frailty, and mutations.
News Author: Thomas R. Collins Publish date: October 26, 2017
SAN FRANCISCO – New therapies for acute myeloid leukemia are finally being developed after a long stagnation.
News Author: Thomas R. Collins Publish date: October 12, 2017
SAN FRANCISCO – The approach to relapsed/refractory multiple myeloma (MM) has to be tailored patient by patient based on the biology of the disease...
News Author: Thomas R. Collins Publish date: October 12, 2017
Measuring MRD makes sense in AML patients in clinical trials, but does not add value in clinical practice.
News Author: Thomas R. Collins Publish date: October 9, 2017
The main challenge for the field is deciding when and how to use the increasing variety of ALL therapies.
News Author: Thomas R. Collins Publish date: September 25, 2017
Nearly a quarter of cancer patients used cannabis in the past year.
News Author: Thomas R. Collins Publish date: September 25, 2017
Primary care physicians falling short with cancer survivors.
News Author: Thomas R. Collins Publish date: August 24, 2017
“Early use of SIRT in combination with first-line oxaliplatin-based chemotherapy cannot be recommended in unselected patients with metastatic color...
News Author: Thomas R. Collins Publish date: August 24, 2017
Use of checkpoint inhibitors recommended for some patients with non–small-cell lung cancer.
News Author: Thomas R. Collins Publish date: August 23, 2017
Practice changes may be necessary.
News Author: Thomas R. Collins Publish date: August 17, 2017
Two drug regimens for diffuse large B-cell lymphoma compared in a phase 3 trial.
News Author: Thomas R. Collins Publish date: August 15, 2017
Eighty percent of ALK-positive anaplastic large cell lymphoma patients in the high-dose group had a complete response, along with 83% given the low...
News Author: Thomas R. Collins Publish date: July 20, 2017
Matching down to the allele level in umbilical cord blood transplantation between unrelated donors results in greater overall survival for those wi...
